CASI Pharma reported it has been approved to begin a China registrational clinical trial of Marqibo®, an in-licensed leukemia drug. CASI acquired China rights to Marqibo from Spectrum Pharma of the US. CASI will enroll adult patients with Philadelphia chromosome–negative (Ph‒) acute lymphoblastic leukemia (ALL) who have failed at least two prior treatments. CASI, which develops drugs for the China market, is headquartered in Maryland with a clinical study operation in Beijing.
Source: China Biotoday
